文献速递血栓与止血贫血与红细胞疾病白血病

吉西他滨联合顺铂对比甲氨蝶呤、长春碱、多柔比星联合顺铂治疗晚期或转移性膀胱癌:一项大型随机跨国多中心III期研究结果

Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study.
PubMed 文献 · J Clin Oncol · 2023-01-01

这项III期随机研究纳入405例既往未接受全身化疗的IV期尿路上皮移行细胞癌患者,比较吉西他滨联合顺铂(GC)与标准MVAC方案。两组总生存相似(HR 1.04,95%CI 0.82-1.32,P=.75),缓解率GC 49%对MVAC 46%;GC组毒性死亡率和3/4级中性粒细胞减少性发热、脓毒症、黏膜炎及脱发均低于MVAC组。结论认为GC提供与MVAC相似的生存获益且安全性更好,应改变晚期或转移性尿路上皮移行细胞癌的标准治疗。

要点

  • GC与MVAC总生存相似(HR 1.04,95%CI 0.82-1.32,P=.75),缓解率GC 49%对MVAC 46%。
  • GC组毒性死亡率1%低于MVAC组3%,3/4级中性粒细胞减少性发热2%对14%。
  • GC组3/4级贫血27%、血小板减少57%高于MVAC组18%、21%。

核心结论

  • GC提供与MVAC相似的生存获益,且安全性和耐受性更好,这一更优的风险获益比应使局部晚期和转移性尿路上皮移行细胞癌的标准治疗由MVAC改为GC。

研究设计与样本

  • 大型随机跨国多中心III期研究,纳入405例IV期尿路上皮移行细胞癌且既往未接受全身化疗的患者,随机分为GC组203例和MVAC组202例。
  • GC方案:吉西他滨1000 mg/m2第1、8、15天,顺铂70 mg/m2第2天;MVAC为标准方案;均每28天重复,最多6个周期。

主要发现

  • 总生存两组相似(HR 1.04;95%CI 0.82-1.32;P=.75),至疾病进展时间(HR 1.05;95%CI 0.85-1.30)、至治疗失败时间(HR 0.89;95%CI 0.72-1.10)和缓解率(GC 49% vs MVAC 46%)亦相似。
  • 更多GC患者完成6个周期治疗且剂量调整更少;毒性死亡率GC组1% vs MVAC组3%。
  • GC组较MVAC组更多患者发生3/4级贫血(27% vs 18%)和血小板减少(57% vs 21%);两组红细胞输注率均为每100个周期13例,3/4级出血或血尿均为2%;血小板输注率GC组每100个周期4例 vs MVAC组每100个周期2例。
  • MVAC组较GC组更多患者发生3/4级中性粒细胞减少(82% vs 71%)、中性粒细胞减少性发热(14% vs 2%)、中性粒细胞减少性脓毒症(12% vs 1%)、3/4级黏膜炎(22% vs 1%)和脱发(55% vs 11%)。
  • 两组治疗期间生活质量均维持;GC组更多患者在体重、体能状态和疲乏方面表现更好。

临床怎么用

  • 作者结论认为GC的风险获益比更优,应使局部晚期和转移性尿路上皮移行细胞癌的标准治疗由MVAC改为GC。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Gemcitabine plus cisplatin (GC) and methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) were compared in patients with locally advanced or metastatic transitional-cell carcinoma (TCC) of the urothelium. PATIENTS AND METHODS: Patients with stage IV TCC and no prior systemic chemotherapy were randomized to GC (gemcitabine 1,000 mg/m2 days 1, 8, and 15; cisplatin 70 mg/m2 day 2) or standard MVAC every 28 days for a maximum of six cycles. RESULTS: Four hundred five patients were randomized (GC, n = 203; MVAC, n = 202). The groups were well-balanced with respect to prognostic factors. Overall survival was similar on both arms (hazards ratio [HR], 1.04; 95% confidence interval [CI], 0.82 to 1.32; P = .75), as were time to progressive disease (HR, 1.05; 95% CI, 0.85 to 1.30), time to treatment failure (HR, 0.89; 95% CI, 0.72 to 1.10), and response rate (GC, 49%; MVAC, 46%). More GC patients completed six cycles of therapy, with fewer dose adjustments. The toxic death rate was 1% on the GC arm and 3% on the MVAC arm. More GC than MVAC patients had grade 3/4 anemia (27% v 18%, respectively) and thrombocytopenia (57% v 21%, respectively). On both arms, the RBC transfusion rate was 13 of 100 cycles and grade 3/4 hemorrhage or hematuria was 2%; the platelet transfusion rate was four patients per 100 cycles and two patients per 100 cycles on GC and MVAC, respectively. More MVAC patients, compared with GC patients, had grade 3/4 neutropenia (82% v 71%, respectively), neutropenic fever (14% v 2%, respectively), neutropenic sepsis (12% v 1%, respectively), and grade 3/4 mucositis (22% v 1%, respectively) and alopecia (55% v 11%, respectively). Quality of life was maintained during treatment on both arms; however, more patients on GC fared better regarding weight, performance status, and fatigue. CONCLUSION: GC provides a similar survival advantage to MVAC with a better safety profile and tolerability. This better-risk benefit ratio should change the standard of care for patients with locally advanced and metastatic TCC from MVAC to GC.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study. J Clin Oncol. 2023. PMID: 37549482. doi:10.1200/JCO.22.02763

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。